<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <schemaVersion>X0202</schemaVersion>
<headerData>
    <submissionType>SCHEDULE 13G/A</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001950105</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>3</amendmentNo>
      <securitiesClassTitle>Common Stock, $0.00001 par value per share</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>09/30/2026</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001759138</issuerCik>
        <issuerName>CABALETTA BIO, INC.</issuerName>
        <issuerCusips>
          <issuerCusipNumber>12674W109</issuerCusipNumber>
        </issuerCusips>
        <issuerPrincipalExecutiveOfficeAddress>
          <street1 xmlns="http://www.sec.gov/edgar/common">2929 Arch Street</street1>
          <street2 xmlns="http://www.sec.gov/edgar/common">Suite 600</street2>
          <city xmlns="http://www.sec.gov/edgar/common">Philadelphia</city>
          <stateOrCountry xmlns="http://www.sec.gov/edgar/common">PA</stateOrCountry>
          <zipCode xmlns="http://www.sec.gov/edgar/common">19104</zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Bain Capital Life Sciences Opportunities III, LP</reportingPersonName>
      <citizenshipOrOrganization>DE</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>0</soleVotingPower>
        <sharedVotingPower>21209188</sharedVotingPower>
        <soleDispositivePower>0</soleDispositivePower>
        <sharedDispositivePower>21209188</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>21209188</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>9.57</classPercent>
      <typeOfReportingPerson>PN</typeOfReportingPerson>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>CABALETTA BIO, INC.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>2929 Arch Street, Suite 600, Philadelphia, Pennsylvania 19104</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>This Schedule 13G is being filed by Bain Capital Life Sciences Opportunities III, L.P., a Delaware limited partnership (the "Reporting Person").

Bain Capital Life Sciences Investors, LLC, a Delaware limited liability company ("BCLSI"), is the manager of Bain Capital Life Sciences III General Partner, LLC, a Delaware limited liability company ("BCLS Fund III GP"), which is the general partner of Bain Capital Life Sciences Fund III, L.P., a Delaware limited partnership ("BCLS Fund III"), which is the sole member of Bain Capital Life Sciences Opportunities III GP, LLC, a Delaware limited liability company (together with the Reporting Person, BCLSI, BCLS Fund III GP and BCLS Fund III, the "Bain Capital Life Sciences Entities"), which is the general partner of the Reporting Person. As a result, BCLSI may be deemed to share voting and dispositive power with respect to the securities held by the Reporting Person.</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>The principal business address for each of the Bain Capital Life Sciences Entities is 200 Clarendon Street, Boston, Massachusetts 02116.</principalBusinessOfficeOrResidenceAddress>
        <citizenship>Each of the Bain Capital Life Sciences Entities is organized under the laws of the State of Delaware.</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>As of the close of business on September 30, 2026, the Reporting Person held 15,209,188 shares of Common Stock and a pre-funded warrant to purchase up to 6,000,000 shares of Common Stock. The Reporting Person is prohibited from exercising the pre-funded warrant to purchase Common Stock if, as a result of such exercise, the Reporting Person would beneficially own more than 9.99% of the total number of shares of Common Stock then issued and outstanding immediately after giving effect to the exercise.

The percentage of the outstanding shares of Common Stock held by the Reporting Person is based on (i) 215,720,392 shares of Common Stock outstanding as of October 30, 2026, as reported by the Issuer in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, filed with the Securities and Exchange Commission on November 5, 2026 and (ii) 6,000,000 shares of Common Stock issuable upon the exercise of the pre-funded warrant held by the Reporting Person.</amountBeneficiallyOwned>
        <classPercent>See Item 4(a) hereof.</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>0</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>See Item 4(a) hereof.</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>0</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>See Item 4(a) hereof.</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>Y</notApplicableFlag>
      </item5>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.</certifications>
      </item10>
    </items>
    <signatureInformation>
      <reportingPersonName>Bain Capital Life Sciences Opportunities III, LP</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Andrew Hack</signature>
        <title>Andrew Hack, Partner of Bain Capital Life Sciences Investors, LLC</title>
        <date>11/16/2026</date>
      </signatureDetails>
    </signatureInformation>
  </formData>
</edgarSubmission>
